Study record · Melanotan II
Melanotan II in men with organic erectile dysfunction
Subjective erections occurred after 12/19 active injections versus 1/21 placebo doses; desire was higher after Melanotan II.
Key result
Subjective erections occurred after 12/19 active injections versus 1/21 placebo doses; desire was higher after Melanotan II.
Study details
Study designDouble-blind, placebo-controlled crossover study
PopulationMen with organic erectile dysfunction
Sample size10
RouteSubcutaneous
Regimen / exposure0.025 mg/kg Melanotan II; each participant received active and placebo exposures
DurationAcute 6-hour monitoring
ComparatorVehicle placebo
Primary endpoint / questionErectile response, rigidity, sexual desire and adverse effects
Safety resultNausea and stretching/yawning were more frequent; 4/19 active injections were associated with severe nausea.
Key limitationsSmall acute study; no long-term efficacy/safety and not an approved ED therapy.
Registry / identifierPMID 11018622